RCUS241220P22500
- 0.00
- 0.000.00%
Arcus Biosciences Newsroom
Barclays Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $29
BofA Securities Maintains Arcus Biosciences(RCUS.US) With Hold Rating, Maintains Target Price $22
Roche Anti-TIGIT Therapy Fails to Extend Survival in Late-stage Lung Cancer Trial
Cautious Outlook on Arcus Biosciences Amid Uncertain TIGIT-Based Treatments
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
Arcus Biosciences Announces New Employment Inducement Grants
Truist Financial Maintains Arcus Biosciences(RCUS.US) With Buy Rating
Analysts Have Made A Financial Statement On Arcus Biosciences, Inc.'s (NYSE:RCUS) Third-Quarter Report
Morgan Stanley Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Raises Target Price to $36
Arcus Biosciences (RCUS) Gets a Buy From Morgan Stanley
A Quick Look at Today's Ratings for Arcus Biosciences(RCUS.US), With a Forecast Between $20 to $29
Promising Developments and Strategic Partnerships Drive Buy Rating for Arcus Biosciences
Arcus Biosciences, Inc. (RCUS) Q3 2024 Earnings Call Transcript Summary
Arcus Biosciences, Inc. (RCUS) Q3 2024 Earnings Call Transcript
Express News | Arcus Biosciences: Believe Cash, Cash Equivalents & Marketable Securities on-Hand to Be Sufficient to Fund Operations Into Mid-2027
Arcus Biosciences | 8-K: Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update
Earnings Flash (RCUS) ARCUS BIOSCIENCES Reports Q3 Revenue $48M
Arcus Biosciences | 10-Q: Q3 2024 Earnings Report
Press Release: Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update
Arcus Biosciences 3Q Loss $92M >RCUS